Detail akcie Anebulo Pharma Rg online

Business Summary: Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous administration. Selonabant is intended to rapidly reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. It is also prioritizing the advancement of a selonabant intravenous (IV) formulation as a potential treatment for pediatric patients with cannabis-induced CNS depression.
Financial Summary: BRIEF: For the six months ended 31 December 2024, Anebulo Pharmaceuticals Inc revenues was not reported. Net loss decreased 10% to $4.7M. Lower net loss reflects General and administrative - Balancing decrease of 38% to $883K (expense), Compensation and related benefits decrease of 34% to $731K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.20 to -$0.17.